Hydroxychloroquine
- Generic Name
- Hydroxychloroquine
- Brand Names
- Plaquenil, Sovuna
- Drug Type
- Small Molecule
- Chemical Formula
- C18H26ClN3O
- CAS Number
- 118-42-3
- Unique Ingredient Identifier
- 4QWG6N8QKH
- Background
Hydroxychloroquine is a racemic mixture consisting of an R and S enantiomer. Hydroxychloroquine is an aminoquinoline like chloroquine. It is a commonly prescribed medication in the treatment of uncomplicated malaria, rheumatoid arthritis, chronic discoid lupus erythematosus, and systemic lupus erythematosus. Hydroxychloroquine is also used for the prophylaxis of malaria in regions where chloroquine resistance is unlikely. It was developed during World War II as a derivative of quinacrine with less severe side effects. Chloroquine and hydroxychloroquine are both being investigated for the treatment of SARS-CoV-2.
The FDA emergency use authorization for hydroxychloroquine and chloroquine in the treatment of COVID-19 was revoked on 15 June 2020.
Hydroxychloroquine was granted FDA approval on 18 April 1955.
A recent study reported a fatality in the group being treated with hydroxychloroquine for COVID-19.
- Indication
Hydroxychloroquine is indicated for the prophylaxis of malaria where chloroquine resistance is not reported, treatment of uncomplicated malaria (caused by P. falciparum, P. malariae, P. ovale, or P. vivax), chronic discoid lupus erythematosus, systemic lupus erythematosus, acute rheumatoid arthritis, and chronic rheumatoid arthritis.
- Associated Conditions
- Acute Rheumatoid Arthritis, Malaria, Porphyria Cutanea Tarda, Q Fever, Sjogren's Syndrome (SS), Systemic Lupus Erythematosus, Uncomplicated Malaria caused by Plasmodium Vivax, Uncomplicated Malaria caused by Plasmodium malariae, Uncomplicated Malaria caused by Plasmodium ovale, Chronic Discoid Lupus Erythematosus (DLE), Chronic Rheumatoid Arthritis, Uncomplicated Malaria caused by Plasmodium falciparum
- Associated Therapies
- -
Epidemiology of SARS-CoV-2 and Mortality to Covid19 Disease in French Cancer Patients
- First Posted Date
- 2020-04-10
- Last Posted Date
- 2020-04-10
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 1000
- Registration Number
- NCT04341207
- Locations
- 🇫🇷
Gustave Roussy, Villejuif, Val De Marne, France
Study of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients: Sarilumab, Azithromycin, Hydroxychloroquine Trial - CORIMUNO-19 - VIRO
- Conditions
- Interventions
- First Posted Date
- 2020-04-10
- Last Posted Date
- 2020-05-06
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 27
- Registration Number
- NCT04341870
- Locations
- 🇫🇷
AP-HP Hôpital Beaujon, Clichy, France
🇫🇷AP-HP Hôpital Pitié Salpétrière, Paris, France
🇫🇷AP-HP Hôpital Avicenne, Bobigny, France
Low-dose Hydroxychloroquine and Bromhexine: a Novel Regimen for COVID-19 Prophylaxis in Healthcare Professionals
- Conditions
- Interventions
- First Posted Date
- 2020-04-09
- Last Posted Date
- 2021-06-29
- Lead Sponsor
- Instituto Nacional de Rehabilitacion
- Target Recruit Count
- 214
- Registration Number
- NCT04340349
- Locations
- 🇲🇽
National Institute of Rehabilitation, Luis Guillermo Ibarra Ibarra, Mexico City, Cdmx, Mexico
Azithromycin Added to Hydrochloroquine in Patients Admitted to Intensive Care With COVID-19: Randomised Controlled Trial
- Conditions
- Interventions
- First Posted Date
- 2020-04-09
- Last Posted Date
- 2020-11-06
- Lead Sponsor
- Frantisek Duska, MD, PhD
- Target Recruit Count
- 3
- Registration Number
- NCT04339816
- Locations
- 🇨🇿
František Duška, Praha, Česká Republika, Czechia
Hydroxychloroquine for the Treatment of Mild COVID-19 Disease
- First Posted Date
- 2020-04-09
- Last Posted Date
- 2020-11-02
- Lead Sponsor
- University Hospital Tuebingen
- Target Recruit Count
- 17
- Registration Number
- NCT04340544
- Locations
- 🇩🇪
Institute for Tropical Medicine, Tübingen, Germany
Hydroxychloroquine, Oseltamivir and Azithromycin for the Treatment of COVID-19 Infection: An RCT
- Conditions
- Interventions
- First Posted Date
- 2020-04-08
- Last Posted Date
- 2022-02-10
- Lead Sponsor
- Shehnoor Azhar
- Target Recruit Count
- 550
- Registration Number
- NCT04338698
- Locations
- 🇵🇰
Gujranwala Medical College, Gujrānwāla, Pakistan
🇵🇰Khyber Teaching Hospital, Peshawar, Pakistan
🇵🇰Akram Medical Complex, Lahore, Pakistan
Combination Therapy With Camostat Mesilate + Hydroxychloroquine for COVID-19
- Conditions
- Interventions
- First Posted Date
- 2020-04-08
- Last Posted Date
- 2020-12-21
- Lead Sponsor
- Heinrich-Heine University, Duesseldorf
- Registration Number
- NCT04338906
HCQ for Primary Prophylaxis Against COVID19 in Health-care Workers
- Conditions
- Interventions
- First Posted Date
- 2020-04-07
- Last Posted Date
- 2022-04-12
- Lead Sponsor
- Medical University of Vienna
- Registration Number
- NCT04336748
Randomized Comparison of Combination Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19
- Conditions
- Interventions
- First Posted Date
- 2020-04-07
- Last Posted Date
- 2023-02-28
- Lead Sponsor
- Rutgers, The State University of New Jersey
- Target Recruit Count
- 75
- Registration Number
- NCT04336332
- Locations
- 🇺🇸
Saint Barnabas Medical Center, Livingston, New Jersey, United States
🇺🇸Robert Wood Johnson University Hopsital, New Brunswick, New Jersey, United States
🇺🇸Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
Hydroxychloroquine vs. Azithromycin for Outpatients in Utah With COVID-19
- First Posted Date
- 2020-04-06
- Last Posted Date
- 2020-04-09
- Lead Sponsor
- Intermountain Health Care, Inc.
- Target Recruit Count
- 1550
- Registration Number
- NCT04334382
- Locations
- 🇺🇸
Intermountain Medical Center, Murray, Utah, United States
🇺🇸University of Utah, Salt Lake City, Utah, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.